Growth Metrics

Trinity Biotech (TRIB) Common Equity (2016 - 2025)

Trinity Biotech's Common Equity history spans 17 years, with the latest figure at -$72.0 million for Q4 2025.

  • On a quarterly basis, Common Equity fell 104.6% to -$72.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$72.0 million, a 104.6% decrease, with the full-year FY2025 number at -$72.0 million, down 104.6% from a year prior.
  • Common Equity hit -$72.0 million in Q4 2025 for Trinity Biotech, down from -$49.5 million in the prior quarter.
  • Over the last five years, Common Equity for TRIB hit a ceiling of -$127000.0 in Q1 2021 and a floor of -$496.0 million in Q2 2021.
  • Historically, Common Equity has averaged -$56.7 million across 5 years, with a median of -$23.4 million in 2023.
  • The widest YoY moves for Common Equity: up 85.62% in 2021, down 69562.92% in 2021.
  • Tracing TRIB's Common Equity over 5 years: stood at -$319000.0 in 2021, then tumbled by 582.13% to -$2.2 million in 2022, then tumbled by 1000.6% to -$23.9 million in 2023, then crashed by 46.9% to -$35.2 million in 2024, then tumbled by 104.6% to -$72.0 million in 2025.
  • Business Quant data shows Common Equity for TRIB at -$72.0 million in Q4 2025, -$49.5 million in Q2 2025, and -$35.2 million in Q4 2024.